Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Number of Participants With Adverse Events

The severity of each adverse event was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal; * life threatening (places the participant at immediate risk of death); * requires in patient hospitalization or prolongation of existing hospitalization; * results in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.

Time frame: From the first dose of study drug up until Day 57

Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes

The investigator reviewed vital signs and laboratory test results and determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.

Time frame: 57 days

Number of Participants With Anti-evolocumab Antibodies

Blood samples were tested using an electrochemiluminescence-based bridging immunoassay to detect antibodies capable of binding to evolocumab.